NCT01044433 · REGISTRY CONDITION SEARCH

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2020-03-19

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving capecitabine together with lapatinib ditosylate may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving capecitabine and lapatinib ditosylate together works in treating patients with squamous cell cancer of the head and neck.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Response Rate

→

outcome · POSTED

Disease Control Rate

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Number of Participants With Adverse Events and Serious Adverse Events

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion * Histologically or cytologically confirmed SCCHN * All primary sites are eligible excluding nasopharyngeal * Metastatic disease or locally recurrent disease not felt amenable to curative therapy (as determined by a physician) * ECOG performance status 0-2 * No prior chemotherapy in the metastatic / locally advanced, recurrent incurable setting; patients may have received prior curative-intention chemotherapy including induction chemotherapy, chemotherapy concurrent with radiation and adjuvant chemotherapy * No prior capecitabine; patients who have received 5-FU or other fluoropyrimidines in the curative-intention setting will not be excluded, as long as more than 6 mos have elapsed since prior 5-FU exposure * No previous history of Lapatinib * Previous use of cetuximab in the curative-intention setting will not result in exclusion, as long as at least four weeks have elapsed since prior C225 exposure * Patients may have received radiation therapy in the definitive, adjuvant or metastatic setting; radiation therapy must be completed at least 14 days prior to study participation * ECOG performance status of 0-2 (Karnofsky \>= 60%) * Must have normal organ and marrow function * Laboratory tests should be completed within 14 days prior to registration * Left ventricular ejection fraction (LVEF) can be determined by either echocardiography or nuclear scintigraphy and should be obtained within 21 days of enrollment * Platelets \>= 100,000/mm\^3 * Total bilirubin =\< 2 * Albumin \> 2.5 * AST(SGOT)/ALT(SGPT) =\< 5.0 X institutional upper limit of normal (for patients with hepatic metastases) =\< 3.0 X institutional upper limit of normal (for patients without hepatic metastases) * GFR \> 30 (by standard Cockroft and Gault formula) * LVEF \>= 50% * Patients may receive anticoagulant medication while on study * Patients may not receive other antineoplastic therapies such as chemotherapy or radiation treatments while on study; patients may not receive other experimental treatments while on study; patients requiring radiation treatments during protocol-based treatment will be taken off study * Patients may receive concurrent bisphosphonate therapy as well as hormonal manipulations for appetite while on study * Patients must neither be pregnant nor expect to become pregnant while on study * Patients must have the ability to understand and the willingness to sign a written informed consent document * Adequate swallowing function or gastric-tube for drug administration * No disability with absorption of internal medications * Adequate nutritional status: Patients will not be excluded based on previous weight loss but will be required to have adequate nutrition at the time of study entry as measured by serum albumin * ANC \>= 1,500/mm\^3 * Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation Exclusion * Patients who have received prior capecitabine chemotherapy or lapatinib * Patients with brain metastases may participate if they have undergone appropriate treatment for the lesion(s), are at least two weeks post treatment without evidence for post-treatment progression, have no significant neurologic symptoms, and are no longer on steroids for brain metastases * Patients with symptoms concerning for CNS metastases should be evaluated with imaging prior to study participation * Less than 3 weeks elapsed since prior exposure to chemotherapy * LVEF \< 50% or symptomatic congestive heart failure (CHF) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded due to the potential for teratogenic or abortifacient effects of capecitabine and lapatinib; because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued prior to participation of the mother on study * Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy within two years; localized squamous cell carcinoma of the skin, basal-cell carcinoma of the skin, carcinoma in-situ of the cervix, or other malignancies requiring locally ablative therapy only will not result in exclusion * Have received treatment within the last 30 days prior to study entry with any drug that has not received regulatory approval for an indication at the time of study entry * Previous CHF or other cardiac conditions shall not result in exclusion if the treating physician does not see contraindication to these medications; if contraindication is controversial, cardiac consultation will be obtained prior to the initiation of therapy * Anti-cancer therapy (other than the investigational regimen) is prohibited from 3 weeks before the first dose of investigational product through discontinuation unless otherwise noted * Investigational drugs are not permitted from 3 weeks (21 days) or 5 half-lives, whichever is longer, prior to the first dose and up through 30 days after the last dose of investigational product * CYP3A4 inducers and inhibitors, antacids, and herbal or dietary supplements * Concurrent radiation therapy and surgery for SCCHN is prohibited during therapy
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.
intervention Names
Drug: lapatinib ditosylate
Drug: capecitabine
label
Arm I
type
EXPERIMENTAL

interventions

arm Group Labels
Arm I
description
Given orally
name
lapatinib ditosylate
other Names
GSK572016
GW-572016
GW2016
lapatinib
Tykerb
type
DRUG
arm Group Labels
Arm I
description
Given orally
name
capecitabine
other Names
CAPE
Ro 09-1978/000
Xeloda
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 44
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

measure
Overall Survival
time Frame
5 years

secondary Outcomes

description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
measure
Response Rate
time Frame
5 years
measure
Disease Control Rate
time Frame
5 years
measure
Progression-free Survival
time Frame
5 years
description
ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE) Adverse Events (AEs) will use the descriptions and grading scales found in the NCI CTCAE v3.0
measure
Number of Participants With Adverse Events and Serious Adverse Events
time Frame
5 years

Full study description

brief Summary: RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving capecitabine together with lapatinib ditosylate may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving capecitabine and lapatinib ditosylate together works in treating patients with squamous cell cancer of the head and neck.
detailed Description: PRIMARY OBJECTIVE: I. Overall survival (OS) will be the primary endpoint. SECONDARY OBJECTIVES: I. Progression free survival (PFS). II. Time to disease progression and sites of progression. III. Response rate. IV. Toxicity of the combination in this population. V. Quality of life. OUTLINE: Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for up to 5 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-14476c4dc51a293230be
requested nct id
NCT01044433
primary nct id
NCT01044433
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Salivary+Gland+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
payload sha256
1825e396422d73b166e1a561c790eb28c2ca1a415fae1924665429fce64116a4
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-14476c4dc51a293230be
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01044433
occurrences
context exact
NCT01044433
end
11
exact text
NCT01044433
start
0
offset unit
unicode_code_points
query cond
Salivary Gland Cancer
query disease state id
ds-salivary-gland-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
source file sha256
38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
source json pointer
/studies/27/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0dca282c96f7f95cd54b69a80034e08026613a065472c6ca139b579c4ddf5377
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Salivary+Gland+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-228803ac85022efb8de2
requested nct id
NCT01044433
primary nct id
NCT01044433
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
payload sha256
e5241225bc2e7fa517ec44832ae478725b71b8677316cc3e25632d281c1b051d
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-228803ac85022efb8de2
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01044433
occurrences
context exact
NCT01044433
end
11
exact text
NCT01044433
start
0
offset unit
unicode_code_points
query cond
Hypopharyngeal Cancer
query disease state id
ds-hypopharyngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
source json pointer
/studies/44/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0dca282c96f7f95cd54b69a80034e08026613a065472c6ca139b579c4ddf5377
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-4090616aebbcd10f175f
requested nct id
NCT01044433
primary nct id
NCT01044433
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Metastatic+Squamous+Neck+Cancer+With+Occult+Primary&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
payload sha256
bbb6aa9194437ac9ca71ad21639853b7ebeebf084e5e3017a172cc355434e52e
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-4090616aebbcd10f175f
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01044433
occurrences
context exact
NCT01044433
end
11
exact text
NCT01044433
start
0
offset unit
unicode_code_points
query cond
Metastatic Squamous Neck Cancer With Occult Primary
query disease state id
ds-metastatic-squamous-neck-cancer-with-occult-primary
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-metastatic-squamous-neck-cancer-with-occult-primary-000.json
source file sha256
2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
source json pointer
/studies/13/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0dca282c96f7f95cd54b69a80034e08026613a065472c6ca139b579c4ddf5377
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Metastatic+Squamous+Neck+Cancer+With+Occult+Primary&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-94cf2080a7369d93ae30
requested nct id
NCT01044433
primary nct id
NCT01044433
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
58edaee6d2ebd0df3f696b387bbf2edb315d6db639fdc6f6b4520511095df6f4
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-94cf2080a7369d93ae30
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01044433
occurrences
context exact
NCT01044433
end
11
exact text
NCT01044433
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/57/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0dca282c96f7f95cd54b69a80034e08026613a065472c6ca139b579c4ddf5377
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice